Neolithic introgression of IL23R-related protection against chronic inflammatory bowel diseases in modern Europeans
- PMID: 39923740
- PMCID: PMC11849592
- DOI: 10.1016/j.ebiom.2025.105591
Neolithic introgression of IL23R-related protection against chronic inflammatory bowel diseases in modern Europeans
Abstract
Background: The hypomorphic variant rs11209026-A in the IL23R gene provides significant protection against immune-related diseases in Europeans, notably inflammatory bowel diseases (IBD). Today, the A-allele occurs with an average frequency of 5% in Europe.
Methods: This study comprised 251 ancient genomes from Europe spanning over 14,000 years. In these samples, the investigation focused on admixture-informed analyses and selection scans of rs11209026-A and its haplotypes.
Findings: rs11209026-A was found at high frequencies in Anatolian Farmers (AF, 18%). AF later introduced the allele into the ancient European gene-pool. Subsequent admixture caused its frequency to decrease and formed the current southwest-to-northeast allele frequency cline in Europe. The geographic distribution of rs11209026-A may influence the gradient in IBD incidence rates that are highest in northern and eastern Europe.
Interpretation: Given the dramatic changes from hunting and gathering to agriculture during the Neolithic, AF might have been exposed to selective pressures from a pro-inflammatory lifestyle and diet. Therefore, the protective A-allele may have increased survival by reducing intestinal inflammation and microbiome dysbiosis. The adaptively evolved function of the variant likely contributes to the high efficacy and low side-effects of modern IL-23 neutralisation therapies for chronic inflammatory diseases.
Funding: German Research Foundation (EXC 2167 390884018 and EXC 2150 390870439).
Keywords: Ancient genomics; Crohn's disease; IL-23-signalling; IL23R; Inflammatory bowel diseases; Ulcerative colitis.
Copyright © 2025 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests related to the conception and results of this study. Financial disclosures: SSch reports lecture and consulting fees from: AbbVie, Alfasigma, Arena, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Falk, Ferring, Fresenius Kabi, Gilead, Hikma, I-Mab, Janssen, Lilly, Pfizer, Protagonist Ther., Provention Bio, Takeda, Ventyx. BKK received speaker's fees from Lilly.
Figures
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
